Application of PET probe targeting sphingomyelin receptor S1PR1 in the preparation of therapeutic efficacy monitoring products for Parkinson's disease
Through the combination of PET probe [18F]TZ4877 targeting the sphingomyelin receptor S1PR1 and montelukast, the problem of difficulty in effectively evaluating the therapeutic effect of montelukast on Parkinson's disease in the prior art is solved, and a sensitive and objective efficacy evaluation is achieved at the molecular level, which has important clinical application value.
CN119746106APending Publication Date: 2025-04-04THE FIFTH AFFILIATED HOSPITAL SUN YAT SEN UNIV
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202411313884.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2025-04-04
AI Technical Summary
Technical Problem
The prior art is difficult to effectively evaluate the therapeutic effect of montelukast on Parkinson's disease, especially in the diagnosis, treatment and evaluation of anti-inflammatory treatment mechanisms and multiple pathological mechanisms.
Method used
The PET probe targeting the sphingomyelin receptor S1PR1 [18F]TZ4877 was used to evaluate the efficacy of Parkinson's disease through its binding to montelukast, and a sensitive and objective evaluation was conducted at the molecular level.
Benefits of technology
It has achieved a sensitive and objective evaluation of the efficacy of montelukast in the treatment of Parkinson's disease, and has great application value in the evaluation of the effectiveness of various anti-inflammatory therapies.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention discloses the use of a sphingomyelin receptor S1PR1PET probe in the preparation of a product for monitoring the therapeutic effect of Parkinson's disease. The sphingomyelin receptor S1PR1PET probe is [ 18 F] TZ4877 probe. The present invention uses a PET probe targeting the sphingomyelin receptor S1PR1 to evaluate the efficacy of montelukast in improving Parkinson's disease. Verification has shown that the PET probe targeting the sphingomyelin receptor S1PR1 can more sensitively and objectively evaluate the efficacy of Parkinson's disease at the molecular level, and has great application value in the objective evaluation of the effectiveness of various anti-inflammatory therapies for Parkinson's disease.
Need to check novelty before this filing date? Find Prior Art